Candel Therapeutics, Inc.
CADL· Nasdaq
Released Mar 12, 2026, before the open
10-K filed Mar 12, 2026, 71 days after period end · 0001193125-26-103134
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | — | — | $32.00K |
| Net Income | -$29.50M |
Candel Therapeutics, Inc. · CIK 1841387 · Engraved from SEC EDGAR
| -$14.07M |
| -$11.10M |
| -$5.08M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.